In human PBMC, dSLIM® shows a superior cytokine secretion and cellular activation pattern and addresses all relevant regulators and effectors of an anti‐tumor response: compared to ProMune® 3 μM dSLIM® evoked more than 40‐fold higher secretion of IFN‐α, a central anti‐cancer cytokine regulating innate and adaptive immune responses 40; dSLIM® evoked almost 100‐fold better secretion of IP‐10, a potent angiostatic factor 41; and dSLIM® evoked a 100% better stimulation of IFN‐γ‐secretion than ProMune®, the key activator of NK cells, NKT cells, and cytotoxic T cell responses 42. The gene discussed is IFNA1; the disease is cancer.